other material
confidence high
sentiment positive
materiality 0.65
Arvinas ARV-806 preclinical data: >90% KRAS G12D degradation for 7 days in xenograft models
ARVINAS, INC.
- ARV-806 degraded KRAS G12D with picomolar potency across pancreatic, colorectal, and lung cancer cell lines without affecting wild-type RAS.
- Compared with clinical-stage inhibitors and another G12D degrader, ARV-806 showed >25-fold greater antiproliferative potency and >40-fold higher degradation potency.
- Single dose degraded >90% of KRAS G12D for 7 days in colorectal xenograft, with c-MYC suppression and BIM induction for ≥5 days.
- Achieved ≥30% tumor volume reductions in pancreatic, colorectal CDX and lung PDX models at low doses.
- Phase 1 trial in KRAS G12D-mutated advanced solid tumors (NCT07023731) ongoing; orally bioavailable pan-KRAS degraders also identified.